Skip to content
    Real-World Studies

    CAR T-Cell Therapy Linked to Higher Severe Neurotoxicity in Octogenarians

    Lee et alBlood neoplasia

    CAR T-Cell Therapy Linked to Higher Severe Neurotoxicity in Octogenarians
    In a single-institution retrospective propensity score-matched study, researchers assessed the safety and efficacy of CD19-directed chimeric antigen receptor (CAR) T-cell therapy in 24 octogenarians (aged ≥80 years) compared with 48 patients aged 65 to 79 years with relapsed or refractory large B-cell lymphoma. Cohorts were matched 2:1 using propensity scoring. Baseline characteristics were comparable between groups, with the exception of higher use of lisocabtagene maraleucel and tisagenlecleucel (P < .001) and bridging therapy (P = .024) in the octogenarian cohort. Median follow-up was 15.8 months for octogenarians and 36.7 months for the comparator cohort.
    Regarding safety outcomes, octogenarians experienced a higher incidence of grade ≥3 immune effector cell-associated neurotoxicity syndrome (ICANS) compared with younger controls (25% vs 21%; average treatment effect [ATE] P = .027). Furthermore, among patients who developed grade ≥3 cytokine release syndrome (CRS) or ICANS, octogenarians had significantly longer hospital stays (30 days vs 16 days; ATE P < .001). In terms of cellular kinetics, CAR T-cell expansion was reduced in the octogenarian cohort, exhibiting lower peak counts (ATE P = .038) and reduced expansion across the 28 days following infusion (ATE P < .01).
    Despite increased severe neurotoxicity and lower cellular expansion, therapeutic efficacy was maintained. Overall and complete response rates were comparable between cohorts. In octogenarians, 6- and 12-month progression-free survival (PFS) rates were 57% and 45%, and overall survival (OS) rates were 88% and 81%, respectively, with no significant differences observed relative to the comparator cohort. The authors suggest that selected octogenarians can tolerate and benefit from standard-of-care CAR T-cell therapy, highlighting the necessity of close monitoring and supportive care strategies to mitigate severe toxicities in this population.

    Key Takeaways

    • Patients aged ≥80 years experienced a higher rate of grade ≥3 immune effector cell-associated neurotoxicity syndrome (ICANS) compared with patients aged 65 to 79 years (25% vs 21%; average treatment effect [ATE] P = .027) and required significantly longer hospital stays when grade ≥3 CRS or ICANS occurred (30 days vs 16 days; ATE P < .001).
    • Six- and 12-month progression-free survival rates were 57% and 45%, and overall survival rates were 88% and 81% in octogenarians, showing no significant differences compared with the 65- to 79-year-old cohort alongside comparable overall and complete response rates.
    • CAR T-cell expansion was reduced in octogenarians, marked by lower peak cell counts (ATE P = .038) and reduced cumulative expansion over 28 days post-infusion (ATE P < .01).